Cambium Bio Completes Successful A$3.0 Million Financing
Cambium Bio Limited (ASX:CMB) has recently completed a significant financing round, raising A$3.0 million to bolster its clinical initiatives in regenerative medicine. The company, recognized for its innovative biologics aimed at eye care and tissue repair, is paving the way for promising developments in ophthalmology.
Highlights from the Financing Round
This capital raising was conducted at a price of A$0.4637 per share, reflecting a discount of 25% compared to the recent five-day Volume Weighted Average Price (VWAP). The strong response to this round is a testament to Cambium Bio's reputation and potential in the market.
Strategic Investments and Contributions
AventuraCell Biomedical Corp joined as a strategic investor, injecting A$1.5 million into the company. Their expertise in cell culture supplements aligns perfectly with Cambium’s vision, particularly regarding their human platelet technology. The involvement of Zheng Yang Biomedical Technology with a contribution of A$0.25 million highlights continued institutional support for the company's growth.
Support from Directors and Investors
Notably, Cambium Bio's management team, including its CEO and directors, participated in the financing, contributing over A$1.2 million. This collective investment showcases their confidence in the innovation and future potential of the company's product pipeline.
Purpose of the Raised Funds
The proceeds from this financing round are earmarked primarily for the Phase 3 clinical development of Elate Ocular®, focusing on addressing dry eye disease. Plans are underway for these crucial clinical trials set to commence in the near future, specifically in calendar Q2 of the following year. Additionally, the funds will ensure liquidity for ongoing operations, allowing Cambium Bio to maintain its trajectory toward commercial success.
Insights from Leadership
Karolis Rosickas, the CEO of Cambium Bio, expressed gratitude for the overwhelming support during this capital raising. He highlighted the strategic partnership with AventaCell as integral to advancing their therapeutic programs. Rosickas underscored the confidence shared by existing shareholders, emphasizing that the aligned vision puts Cambium Bio in an excellent position for future growth in the regenerative medicine landscape.
Conclusion
As Cambium Bio moves forward with its financing initiatives, industry watchers are keenly interested in the outcomes of the upcoming clinical trials for Elate Ocular®. The strategic investments and significant contributions from both new and existing investors showcase a robust belief in the company's potential to make significant advancements in the treatment of eye diseases.
Frequently Asked Questions
What is the purpose of the A$3.0 million raised?
The funds will be primarily used to advance Phase 3 clinical trials for Elate Ocular®, targeting dry eye disease, and to support ongoing operations.
Who are the new investors in Cambium Bio?
AventaCell Biomedical Corp is the primary new strategic investor, contributing A$1.5 million to the financing round.
What does the strong investor support indicate?
It reflects confidence in Cambium Bio's strategy and the clinical and commercial potential of its innovative solutions.
When are the Phase 3 trials for Elate Ocular® expected to start?
These trials are planned to commence in calendar Q2 of the following year.
Who can be contacted for more information about Cambium Bio?
For inquiries, individuals can contact Helen Leung, Corporate Secretary, at info@cambium.bio or by phone at 1 300 995 098.
